A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients.
Publication type | Journal Article
|
Authors | |
Keywords | |
Abstract | BACKGROUND: The marked excess in cardiovascular mortality that results from uremia remains poorly understood. METHODS AND RESULTS: In 2 independent, nested case-control studies, we applied liquid chromatography-mass spectrometry-based metabolite profiling to plasma obtained from participants of a large cohort of incident hemodialysis patients. First, 100 individuals who died of a cardiovascular cause within 1 year of initiating hemodialysis (cases) were randomly selected along with 100 individuals who survived for at least 1 year (controls), matched for age, sex, and race. Four highly intercorrelated long-chain acylcarnitines achieved the significance threshold adjusted for multiple testing (P CONCLUSIONS: Our data highlight clinically meaningful alterations in acylcarnitine homeostasis at the time of dialysis initiation, which may represent an early marker, effector, or both of uremic cardiovascular risk. |
Year of Publication | 2013
|
Journal | J Am Heart Assoc
|
Volume | 2
|
Issue | 6
|
Pages | e000542
|
Date Published | 2013 Dec 05
|
ISSN | 2047-9980
|
URL | |
DOI | 10.1161/JAHA.113.000542
|
PubMed ID | 24308938
|
PubMed Central ID | PMC3886735
|
Links | |
Grant list | K08 DK090142 / DK / NIDDK NIH HHS / United States
K24 DK094872 / DK / NIDDK NIH HHS / United States
K08-DK-090142 / DK / NIDDK NIH HHS / United States
R21-DK-071674 / DK / NIDDK NIH HHS / United States
|